glp3.wiki
Regulatory status

Editorially reviewed · Last updated September 8, 2026 · How we review

Ozempic vs Wegovy: Same Drug, Different Purpose

Part of Weight Loss Drug Comparison Index.

Ozempic vs Wegovy: Same Drug, Different Purpose

Ozempic and Wegovy both contain semaglutide, but their approved indications, formulations and doses differ. In the United States, Ozempic products treat type 2 diabetes and have specified cardiovascular indications; the injection also has a kidney-risk indication. Wegovy products are used for weight management and specified cardiovascular risk reduction. Wegovy injection also has an indication for certain adults with MASH.

Understanding the difference matters for insurance coverage, prescribing, and what you can expect from each.

Side-by-Side Comparison

US labelingOzempicWegovy
Active ingredientSemaglutideSemaglutide
Main treatment populationAdults with type 2 diabetesEligible people with obesity or overweight; age and indication depend on formulation
Injection doseUp to 2 mg once weekly for glycemic controlUsually 2.4 mg; up to 7.2 mg for eligible adults needing further weight reduction
TabletsOzempic tablets: 1.5 mg starting dose, 4 or 9 mg maintenance1.5, 4 and 9 mg escalation; 25 mg maintenance
Cardiovascular indicationInjection: T2D plus established CVD; tablets: T2D plus high CV riskEstablished CVD plus obesity or overweight
Other indicationInjection: reduce specified kidney/CV risks in adults with T2D and CKDInjection: noncirrhotic MASH with F2–F3 fibrosis in adults, under accelerated approval
These are product-specific distinctions. Tablet and injection milligrams are not interchangeable; neither are Ozempic and Rybelsus tablet formulations on a milligram-for-milligram basis. See the Ozempic injection label, Ozempic tablet label and Wegovy label.

Why the Same Drug Has Two Names

Ozempic injection was first approved in 2017 for type 2 diabetes, and Wegovy injection in 2021 for weight management. Separate development programs established different doses and clinical outcomes. Later indications and tablet formulations mean that “diabetes injection versus weight-loss injection” is now an incomplete description.

The brand name matters because prescribing, devices and insurance authorization follow the specific product and indication. It does not make semaglutide a different molecule.

Dosing Differences

For injections, Ozempic starts at 0.25 mg weekly and can be increased, under its label, to a maximum of 2 mg for glycemic control. Wegovy injection has a different escalation and maintenance schedule. Its current label includes 7.2 mg for eligible adults who tolerate 2.4 mg and need further weight reduction.

Daily tablets use different doses and absorption rules. Ozempic tablets have 4 or 9 mg maintenance doses after a 1.5 mg start; Wegovy tablets have a 25 mg maintenance dose after escalation. Both must be taken on an empty stomach in the morning with up to 4 ounces of water, followed by at least 30 minutes before food, drink or other oral medicines.

These facts explain the products; they are not a conversion schedule. A prescriber should identify the exact formulation and indication before changing treatment.

Weight Loss at Different Doses

Weight-loss results must stay attached to the formulation, population and duration studied. STEP obesity studies are not Ozempic diabetes trials.

Swipe sideways to see every column.

Studied treatmentPopulation and durationWeight resultInterpretation
Semaglutide 2.4 mg injection, STEP 1Adults with overweight/obesity without diabetes; 68 weeks14.9% mean reductionTreatment-policy estimate; not a result for every semaglutide product
Ozempic 2 mg injection, NCT03989232Adults with T2D on metformin with/without sulfonylurea; 40 weeks6.4 kg reduction versus 5.6 kg with 1 mgLabel analysis; weight difference was not statistically significant
Semaglutide 50 mg tablet, OASIS 1Adults with overweight/obesity without diabetes; 68 weeks15.1% mean reductionHistorical investigational dose; marketed Wegovy tablets use 25 mg

These separate trials do not isolate a brand effect or predict an individual’s weight loss. Population, duration, dose and handling of discontinuation all matter. Newer Wegovy 25 mg tablet and 7.2 mg injection results should be read with their own trial designs, rather than replacing the labels on older numbers.

Insurance and Coverage Differences

Coverage depends on the exact product, diagnosis, insurer, formulary and current benefit rules. A diabetes prescription does not automatically qualify a person without diabetes for Ozempic coverage, and an approved obesity indication does not guarantee a plan will cover Wegovy.

Ask the plan or pharmacy to check the specific formulation, approved indication, prior authorization criteria and out-of-pocket cost. Medicare and commercial-plan rules can differ and change; broad claims that one brand is always covered or cheaper are unreliable.

Oral Wegovy

Wegovy tablets were approved in December 2025. Their maintenance dose is 25 mg once daily, following escalation—not the 50 mg investigational regimen used in OASIS 1. Taking them correctly requires the fasting and water instructions in the label.

Oral semaglutide for diabetes also exists as Rybelsus and Ozempic tablets. These formulations have different tablet strengths and should not be exchanged by matching milligrams.

Off-Label Use Considerations

A clinician may prescribe Ozempic for an off-label purpose, but that does not change its approved indications or guarantee insurance payment. For a primary weight-management goal, the conversation should cover an approved treatment’s eligibility, tolerability, formulation, other health conditions and cost.

Do not combine semaglutide products to reach a desired dose. Use the specific product’s instructions and a prescriber’s treatment plan.

Beyond Semaglutide: The Next Generation

Tirzepatide activates GIP and GLP-1 receptors and is marketed under indication-specific brands, including Zepbound and Mounjaro. See Mounjaro vs Ozempic and Zepbound vs Wegovy for the relevant comparisons.
Retatrutide activates those receptors plus glucagon and remains investigational. Lilly plans a US filing in the first quarter of 2027; that is not an approval date. Results from separate trials do not establish that adding receptors will work better for a particular person. See Retatrutide vs Wegovy.

Frequently Asked Questions

Are Ozempic and Wegovy the same drug?

They contain the same active ingredient, semaglutide. Their indications, formulations, doses and instructions differ. Ozempic and Wegovy each have injection and tablet labeling; matching milligrams is not a safe way to substitute them.

Why is Wegovy more expensive than Ozempic?

The premise is not always true for a particular patient. List prices, insurance benefits, pharmacy prices and manufacturer programs are different measures. Check a current quote for your exact prescription rather than assuming a fixed price gap.

Can I use Ozempic instead of Wegovy for weight loss?

Ozempic may be prescribed off-label, but it is not automatically equivalent to a Wegovy prescription. Discuss the intended indication, formulation, dose and coverage with your prescriber.

Does Wegovy come as a pill?

Yes. Wegovy tablets have a 25 mg daily maintenance dose after escalation and must be taken under specific fasting and water instructions. OASIS 1’s 50 mg study dose is not the marketed maintenance dose.

Which has better insurance coverage — Ozempic or Wegovy?

It depends on your diagnosis and plan. Ask for a formulary and prior-authorization check for the specific product; neither brand guarantees coverage.

What is the difference between Ozempic and Rybelsus?

Rybelsus is an oral semaglutide product. Ozempic has both injection and tablet labeling. Rybelsus tablets use 3, 7 or 14 mg, while Ozempic tablets use 1.5, 4 or 9 mg; these formulations are not interchangeable milligram for milligram.

Sources

How we keep this honest
What this is
Educational information, not medical advice. It reports published research — it doesn’t recommend that you use, obtain, or supply anything.
Regulatory status
Ozempic and Wegovy are FDA-approved semaglutide products with different indications, formulations and doses.
Our standard
Every claim traces to a primary source. We label the strength of evidence and flag estimates as estimates — never as clinical fact.
No commercial ties
We don’t sell, supply, or link to suppliers of any medicine, and aren’t affiliated with any manufacturer.

Do not make decisions about your health without consulting a qualified healthcare provider. For trial enrolment, see ClinicalTrials.gov. More on how we review.

Grounded in primary sources
NEJMThe LancetJAMAFDAClinicalTrials.gov

Keep exploring

Explore all compare topics →